Literature DB >> 7874879

Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

M A Pfaller1, S A Messer, R J Hollis.   

Abstract

Candida lusitaniae is an important nosocomial pathogen that may express resistance to one or more antifungal agents including amphotericin B. We investigated the genotypic diversity and antifungal susceptibility among 47 clinical isolates from 33 patients hospitalized in 12 different medical centers. Strain delineation was performed by restriction endonuclease analysis of genomic DNA (REAG) with the restriction enzyme Sfi I followed by pulsed-field gel electrophoresis and by electrophoretic karyotyping (EK). Antifungal susceptibility of the isolates to amphotericin B, 5-fluorocytosine (5FC), fluconazole, and itraconazole was determined using National Committee for Clinical Laboratory Standards standard methods. Minimum inhibitory concentration (MIC)90 values ranged from 0.5 micrograms/ml for itraconazole to 512 micrograms/ml for 5FC. In general, isolates from a given patient or epidemiologically related isolates from a nosocomial cluster were identical by molecular typing methods. Epidemiologically unrelated isolates were all distinctly different by both EK and REAG typing methods. Although elevated amphotericin B MICs ( > or = 2 micrograms/ml) were observed in only three isolates, extended incubation (72 h) revealed amphotericin B MICs of 2-16 micrograms/ml in a subset of isolates suggesting potential amphotericin B resistance. These data document the genetic diversity, nosocomial transmission, and antifungal susceptibility of clinical isolates of C. lusitaniae.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7874879     DOI: 10.1016/0732-8893(94)90106-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  27 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

3.  Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.

Authors:  Carolina Rodrigues Costa; Janine Aquino de Lemos; Xisto Sena Passos; Crystiane Rodrigues de Araújo; Ana Joaquina Cohen; Lúcia Kioko Hasimoto E Souza; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2006-07       Impact factor: 2.574

Review 4.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 5.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae.

Authors:  Florence Chapeland-Leclerc; Julien Bouchoux; Abdelhak Goumar; Christiane Chastin; Jean Villard; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Alternative identification test relying upon sexual reproductive abilities of Candida lusitaniae strains isolated from hospitalized patients.

Authors:  F François; T Noël; R Pépin; A Brulfert; C Chastin; A Favel; J Villard
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

8.  Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.

Authors:  Claire M Hull; Oliver Bader; Josie E Parker; Michael Weig; Uwe Gross; Andrew G S Warrilow; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

Review 9.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

10.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.